The tweet was deleted by the author.
But we saved everything 🙂.
NeoGenomics announced that its webinar on liquid biopsy testing for diagnosis and treatment selection is now available to stream on demand.
The company stated the session covers clinical applications, real-world case studies and implementation strategies. Viewers can watch the full recording online.
View post on X Loading...
NeoGenomics (NEO) is trading at $13.24, sitting below the SMA-20 ($14.40) but above the SMA-50 ($12.08) and SMA-200 ($10.72). This positions NEO under short-term and medium-term selling pressure, while longer-term uptrends remain intact. The Ichimoku Kijun at $13.07 acts as immediate support. Near-term support is at $13.07 (Kijun), with key support at $12.08 (SMA-50). Near-term resistance lies at $14.40 (SMA-20), and key resistance stands at $14.21 (SMA-10 EMA cluster).
MACD on D1 indicates strong bullish momentum, supported by a robust ADX value, although RSI (45.73), Stoch RSI (0.00), CCI (–199.79), and BBP (0.02) all flag oversold conditions, pointing to short-term seller dominance. The Awesome Oscillator remains neutral, not confirming the prevailing trend. Over the past week, NEO has fallen $0.65 (5.40%) from last week's close at $13.89, now trading near the very bottom of its weekly range. Weekly volatility stands at 11.75%. This price action reflects a steady decline from the high, with momentum indicators on D1 diverging as medium-term sells outweigh long-term buy signals.
Looking ahead, the expected price range for NEO over the next week is $12.60 to $13.90, adjusted for recent volatility and anchored within the current price band. Given that RSI-W1, ADX-W1, MACD-W1, and the SMA-50-W1 all issue Buy signals, the probability of a price increase is very high (more than 80%), making a further decline much less likely. Baseline scenario: NEO consolidates within $12.60–$13.90 as oversold conditions attract buyers. Bullish scenario: A move above $13.90 could target the $14.40 resistance area. Bearish scenario: If $13.07 breaks, watch for extended downside toward $12.08. This range keeps NEO well clear of its 52-week low ($4.72) and within reach of the yearly high ($15.57).
Previously it was reported that NeoGenomics maintained a bullish technical backdrop despite short-term selling pressures and mixed momentum indicators. This article expands on that outlook with updated analysis, highlighting the importance of monitoring for a decisive move that could signal either a renewed uptrend or deeper consolidation in the current environment.